Can analysts adopt a bullish outlook for Medifast Inc (NYSE:MED)?

July 14, 2017 - By Henry Gaston

 Can analysts adopt a bullish outlook for Medifast Inc (NYSE:MED)?
Investors sentiment decreased to 1.11 in Q4 2016. Its down 0.30, from 1.41 in 2016Q3. It dived, as 12 investors sold Medifast Inc shares while 53 reduced holdings. 19 funds opened positions while 53 raised stakes. 10.30 million shares or 1.41% more from 10.16 million shares in 2016Q3 were reported.
Bessemer Gru Inc invested in 0% or 24,800 shares. The Ontario – Canada-based Td Asset Mgmt has invested 0% in Medifast Inc (NYSE:MED). Tower Research Cap Limited Liability (Trc) holds 0% or 2 shares in its portfolio. Mutual Of America Capital Management Ltd Co has 1,735 shares. Hl Svcs Lc owns 7,969 shares. Cambridge Invest Research Inc reported 5,082 shares stake. North Star Inv Management Corporation holds 800 shares. Pennsylvania-based Federated Incorporated Pa has invested 0.01% in Medifast Inc (NYSE:MED). Jacobs Levy Equity Mngmt invested 0.02% in Medifast Inc (NYSE:MED). 79,713 were reported by Clarivest Asset Limited Liability. Northern Tru has 138,165 shares for 0% of their portfolio. Bankshares Of Montreal Can invested in 826 shares. Susquehanna Intll Grp Inc Ltd Liability Partnership has 0% invested in Medifast Inc (NYSE:MED). Cadence Mngmt Limited Company stated it has 24,308 shares or 0.07% of all its holdings. Menta Cap Limited Liability stated it has 0.39% in Medifast Inc (NYSE:MED).

Since March 10, 2017, it had 1 insider purchase, and 0 selling transactions for $706,143 activity. Welling Glenn W. also bought $706,143 worth of Medifast Inc (NYSE:MED) shares.

Medifast Inc (NYSE:MED) Ratings Coverage

Among 2 analysts covering Medifast (NYSE:MED), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Medifast had 5 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Medifast Inc (NYSE:MED) earned “Buy” rating by Sidoti on Monday, October 5. The rating was downgraded by Sidoti to “Neutral” on Monday, November 30. The rating was upgraded by Sidoti on Monday, January 11 to “Buy”. The stock of Medifast Inc (NYSE:MED) has “Hold” rating given on Friday, January 29 by Wunderlich. The firm earned “Hold” rating on Monday, August 10 by Zacks. Below is a list of Medifast Inc (NYSE:MED) latest ratings and price target changes.

About 39,941 shares traded. Medifast Inc (NYSE:MED) has risen 25.81% since July 14, 2016 and is uptrending. It has outperformed by 9.11% the S&P500.

Medifast, Inc. is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. The company has market cap of $486.13 million. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins. It has a 24.8 P/E ratio. The Firm provides weight loss, weight management and healthy living products and programs through multiple channels of distribution, which include Take Shape For Life; its direct to consumer business unit through its Website and in-house call centers; Franchise Medifast Weight Control Centers, and a national network of physicians.

More notable recent Medifast Inc (NYSE:MED) news were published by: which released: “Medifast Is Overweight With Inventory. Will Margins Slim Down?” on June 01, 2017, also with their article: “Medifast, Inc. Announces Fourth Quarter and Full Year 2016 Financial Results” published on March 09, 2017, published: “Take Shape For LifeĀ® Named to 2017 Direct Selling Association Top 20 List” on June 20, 2017. More interesting news about Medifast Inc (NYSE:MED) were released by: and their article: “Medifast, Inc. Announces First Quarter 2017 Financial Results” published on May 04, 2017 as well as‘s news article titled: “BRIEF-Medifast Inc may repurchase up to 850000 shares of common stock” with publication date: June 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.